Melio is developing its product portfolio based on proprietary AI-enabled DNA melting technology for rapid and accurate identification of pathogen targets. The technology platform enables identification and quantification of up to 80 pathogen targets in a single culture-free test. Melio's current efforts are focused on delivering a low-cost, in-hou... Read more
Melio's first product will test for most common 30 bacteria, fungi and viruses responsible for 98% of neonatal sepsis cases from the small volume newborn blood samples providing 5X more coverage over the state of art FDA approved tests. Our platform will be competitively priced, and our business model focuses on selling single-use cartridges. As th... Read more